



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17223-002001	Application No. 09/998,497
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Paul O.P. Ts'o et al.	
		Filing Date November 30, 2001	Group Art Unit 1623

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>Ho</i>	AA	5,457,187	10/10/1995	Gmeiner et al.	536	25.5	
<i>Ho</i>	AB	5,614,505	3/25/1997	Gmeiner et al.	514	50	
<i>Ho</i>	AC	5,663,321	9/2/1997	Gmeiner et al.	536	25.5	
<i>Ho</i>	AD	5,741,900	4/21/1998	Gmeiner et al.	536	25.31	
<i>Ho</i>	AE	6,342,485	1/29/2002	Gmeiner et al.	514	44	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AF							
	AG							
	AH							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
<i>Ho</i>	AI	Desmoulin et al., "Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats..." Xenobiotica 33(3):289-303, 2003.
<i>Ho</i>	AJ	Di Stefano et al., "Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-L-lysine to reduce extrahepatic toxicity..." Ital. J. of Gastroenterol Hepatol. 30:173-177, 1998.
<i>Ho</i>	AK	Rohlf et al., "Hepatocyte-activated glycol-conjugated 5-FU prodrug inhibits liver colonies of rat sarcoma" Pharmacology/Therapeutics: Proc. of the American Assoc. for Cancer Res. (abstract) 38:10, 1997.
<i>Ho</i>	AL	Schwartz et al., "Characterization of the Asialoglycoprotein Receptor in a Continuous Hepatoma Line" J. of Biol. Chem. 256(17):8878-8881, 1981.
<i>Ho</i>	AM	Schwartz et al., "Kinetics of Internalization and Recycling of the Asialoglycoprotein Receptor in a Hepatoma Cell Line" J. of Biol. Chem. 257(8):4230-4237, 1982.
<i>Ho</i>	AN	Sharma et al., "Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver" Cancer Chemother. Pharmacol. 48:197-201, 2001.

Examiner Signature <i>David Jones</i>	Date Considered <i>6/25/05</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	